Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies(The University of Texas MD Anderson Cancer Center), Georgina V. Long(The University of Sydney), Keith T. Flaherty(Cancer Research Center), Célèste Lebbé(Inserm), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Stergios J. Moschos(University of North Carolina at Chapel Hill), Jean‐Jacques Grob(Aix-Marseille Université), David Hogg(University of Leeds), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Iván Márquez‐Rodas(Hospital General Universitario Gregorio Marañón), Laurent Mortier, L. Thomas(University of Liverpool), Bijoyesh Mookerjee(Novartis (United States)), Ying Zhang(Boston Children's Hospital), Caroline Robert(Institut Gustave Roussy), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Yingjie Huang, Ana Arance(Hospital Clínic de Barcelona)
Cited by 780
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k